[ad_1]
Over the past five years, clinical research in England has shown year-to-year growth in both the number of new openings and the number of patients recruited, said Matt Cooper, Clinical Research Network. of the National Institute of Health Research (NIHR) (CRN). ), Director of Business Development and Marketing.
The NIHR recently released figures – from April 2018 to March 2019 – which indicate a record number of patients participating in clinical research. "We have recorded the highest participation rates ever recorded this year (more than 870,000) and we want to maintain this strong level of recruitment in the coming years,"Cooper told us.
Over the past 12 months, the NHRI has published a record number of new studies (2,194), bringing the total number of studies underway in England to 6,106, the highest number ever. according to the INDH.
Aditionellement, "each"According to the report, the confidence of the National Health Service (NHS) across the country has recruited patients in the NHRI studies for the first time since 2015/16.
The focus is also on support for commercial clinical trials, such as the government "Recognizes the life sciences sector as a key contributor"To the commercial community of the United Kingdom," said Cooper.
Strengthening the clinical research environment in the United Kingdom is one of the key commitments set out in the recent industry strategy and sectoral agreement in the life sciences sector.
In addition, NIHR CRN has launched national campaigns such as "I am researching" and "Participating in research" to raise public awareness of clinical research as part of the NHS long-term plan – a key element of which is to increase the number of participating patients. in research.
The long-term planA flawless stay
NHS England's long-term plan is a GBP 20.5 billion ($ 25.98 billion) investment focused on service delivery in the NHS. Cooper said the goal is to move the NHS delivery model to preventative care and integration into community-based services for patients with chronic diseases, with priority given to mental health, maternity and childbirth. Cancer. It will also focus on preventing health inequalities.
"As a research network, we are flexible enough to respond to changing patterns of health care delivery and hence to the areas in which research is needed."Added Cooper. "We are looking to adapt to more research in primary care settings, but we also need the life sciences sector to be alert to changes and have protocols that allow primary care as a whole. than search site. "A flawless stay
However, historically, the change has been fairly conservatively addressed, Cooper said, adding that the industry should also look for other types of staff who might work as a senior investigator, such as consulting nurses. .
In order to facilitate change, the NHRI uses its research targeting tool – which uses NHS data to map the prevalence of the disease – to help identify areas of burden of the disease. This map can then be superimposed on a map showing where the search is currently in progress in order to "Study promoters" encourage "to open sites where there are the most needs and to target the patient population",Said Cooper.
Address Brexit and dispel worriesA flawless stay
Although uncertainties and mixed reports circulate, Mr Cooper said that England continued to see an increase year by year in the number of commercial clinical trials entering the UK.
"The life sciences industry still views the UK as a key market for conducting clinical trials – we have excellent facilities, key opinion leaders and can produce quality data in a timely manner. This will always be the case after Brexit ",Said Cooper.
The role of the qualified person (QP) is one of the specific concerns raised about post-Brexit operations. Cooper said the concerns should be eased, however, the Medicines and Healthcare Regulation Agency (MHRA) said any PQ carried out in the EU will only be subject to "A light criticism"In the UK, rather than a complete QP check.
"The trials are global and many countries provide data to a single study that is then merged and packaged to be presented to the regulator of the country in which the sponsor wishes to obtain marketing approval,"He added. "The UK will continue to provide excellent data before and after Brexit. We have not yet entered Brexit, so nothing has changed fundamentally for the moment. "A flawless stay
Source link
